Trysberg et al. showed that the low levels of amyloid β found in SLE patients seemed to be a direct consequence of diminished production of amyloid precursor protein, probably mediated by heavy anti-inflammatory/immunosuppressive therapy [29–31]. This evidence concerns the gene APP and systemic lupus erythematosus.